Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SON-1010 in Healthy Adults
NCT05408572Phase 1Completed
- Sponsor
- Sonnet BioTherapeutics
- Start
- Jul 2022
- Primary completion
- Feb 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SON-1010 in solid tumor, ovarian cancer and sarcoma (5 cohorts), sponsored by Sonnet BioTherapeutics. Primary endpoint: Safety and Tolerability of SON-1010 at Day 29. Started Jul 2022; status: completed.
02
Drugs
SON-1010
03
Conditions
solid tumorovarian cancersarcoma
Beyond the preview
Go deeper on NCT05408572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05408572.